Ardelyx has been granted a patent for a compound that inhibits the enzyme 11-HSD2, useful in treating hyperkalemia by preventing cortisol oxidation. The compound of formula I or its salt allows cortisol to occupy the mineralocorticoid receptor, stimulating potassium excretion. GlobalData’s report on Ardelyx gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Ardelyx Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ardelyx, Peptide pharmacophores was a key innovation area identified from patents. Ardelyx's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.

Compound for treating hyperkalemia by inhibiting enzyme 11-hsd2

Source: United States Patent and Trademark Office (USPTO). Credit: Ardelyx Inc

The granted patent (Publication Number: US11858959B2) discloses a compound of formula I or its salt, with specific structural variations outlined in claims 2 to 17. The compound is designed to inhibit the conversion of cortisol to cortisone by 11ß-HSD2, offering potential therapeutic applications in treating diseases or conditions mediated by this conversion in mammals. Additionally, the compound is also indicated for promoting potassium ion secretion into the colonic lumen and treating hyperkalemia in mammals.

Furthermore, the patent includes methods for administering the compound to achieve the desired therapeutic effects, such as inhibiting cortisol conversion, treating related conditions, promoting potassium ion secretion, and managing hyperkalemia. The pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier, diluent, or excipient is also detailed, providing a comprehensive framework for utilizing the compound in medical interventions. Overall, the patent presents a novel approach to modulating cortisol metabolism and potassium ion secretion, potentially offering new avenues for the treatment of relevant diseases and conditions in mammals.

To know more about GlobalData’s detailed insights on Ardelyx, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies